Skip to main content

Quince Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

QNCX$31.73+8.1%Stored close · as of Oct 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share and per share amounts)

For the three months ended March 31, 2024 and 2023
Common Stock · AdditionalPaid in · Accumulated OtherComprehensive · Accumulated · Total Stockholders'
Shares · Amount · Capital · Income / (Loss) · Deficit · Equity
Balance January 1, 202442,973,215$43$401,638$3,047$(319,644)$85,084
Issuance of common stock on exercise of stock options and vesting of restricted stock units242,018—190——190
Stock based compensation——1,274—1,274
Foreign currency translation adjustment———(1,229)—(1,229)
Unrealized gain on available for sale investments———7—7
Net loss————(11,149)(11,149)
Balance March 31, 202443,215,233$43$403,102$1,825$(330,793)$74,177
Balance January 1, 202336,136,480$36$389,105$(289)$(288,259)$100,593
Issuance of common stock on exercise of stock options and vesting of restricted stock units141,953—56——56
Stock based compensation——1,481——1,481
Foreign currency translation adjustment———92—92
Unrealized gain on available for sale investments———235—235
Net loss————(12,254)(12,254)
Balance March 31, 202336,278,433$36$390,642$38$(300,513)$90,203
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.